Research News

AlphaNet Reaches $25 Million Donation Milestone to Help “Alphas”

1.7 from 6 votes
Tuesday, March 03, 2009

Miami -- AlphaNet, Inc., a not-for-profit specialty disease management organization, has reached the $25 million level in donations to the Alpha-1 Foundation, according to AlphaNet CEO Robert C. Barrett.

Barrett announced the milestone to his Board at their February 2009 meeting, recently held in Coral Gables, Florida.

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic disorder causing life-threatening liver and lung disease. Those diagnosed with the disorder refer to themselves as “Alphas.”

Founded in 1995, AlphaNet has consistently supported the Alpha-1 Foundation with funding for important research efforts, as well as specialized programs benefiting the Alpha community. AlphaNet serves thousands of clients in the United States, Puerto Rico and the U.S. Virgin Islands with 25 Patient Service Coordinators located throughout the United States.

“Through cautious management, tight fiscal controls and creative entrepreneurship, our AlphaNet team has been able to consistently dedicate our excess revenues to the Foundation,” explained Barrett.

Since its inception in 1995, the Alpha-1 Foundation has derived nearly 50 percent of its gross revenues from AlphaNet, according to John W. Walsh, Founder and CEO of the Alpha-1 Foundation.

“The Alpha-1 community is incredibly grateful to AlphaNet for their significant contributions to the Foundation, which positively impact the life of every Alpha,” said Walsh. “The Foundation has supported Alpha-1 research and programs in nearly 70 institutions in North America and Europe.”

AlphaNet makes available a wide range of customized patient care, education and integrated support services to Alpha-1 patients. Programs include a comprehensive disease management and prevention program to improve the quality of life of those affected by Alpha-1. The firm also initiates research and works in support of pharmaceutical-sponsored clinical trials to aid Alphas.

“Talecris is proud of our 13-year partnership with AlphaNet that has helped support Alpha-1 research. Their patient-driven health management model is a crucial component of our Prolastin Direct℠ program for Alpha-1 patients said Lawrence D. Stern, Chairman and CEO, Talecris Biotherapeutics, Inc. “The model of having ‘Alphas serving Alphas’ to improve quality of life through better disease understanding is a best-in-class practice for all rare diseases.”

Over 75 percent of AlphaNet’s employees, and eight of the 11 members of the Board of Directors, are Alphas. Board members are also geographically dispersed throughout the U.S. and include: Robert C. Barrett - Florida, Richard A. Bueker - Missouri, Bonnie J. Chakravorty, MSW, PhD - Tennessee, Robert L. Greene, Jr. - Michigan, Patricia A. Masterson, RN - Rhode Island, Michael R. McConnell, RPh - Indiana, Ab Rees - Missouri, Robert A. Sandhaus, MD, PhD - Colorado, Andrew Steele - Florida, John W. Walsh - Florida, and Grant M. Wood - Utah.

For more about services, news or medical information, visit AlphaNet at

Alpha-1 Antitrypsin Deficiency (Alpha-1) is one of the most prevalent, potentially lethal, hereditary disorders in the United States. Discovered in 1963, Alpha-1 can cause life-threatening, COPD-related lung and/or liver disease. It is a leading genetic killer of adults and a leading cause of liver transplants in children. It is estimated that 20 million Americans are undetected carriers of the Alpha-1 gene and may be at risk for lung and/or liver disease. Approximately 100,000 individuals have the severe deficiency of Alpha-1, yet only about 6,000 have been accurately diagnosed. For more information about AlphaNet or Alpha-1 visit

Contact: Robert C. Barrett, CEO AlphaNet, 305-648-9540

Source: AlphaNet, Inc.
1.7 from 6 votes
Free Newsletter
Related Videos